Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02940730 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02940730 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 10 participants.
The verdict
NCT02940730, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacokinetic properties of dalbavancin when administered as an intravenous infusion and instilled into the peritoneal space in patients who are undergoing peritoneal dialysis. The patients will receive intravenous dalbavancin followed by intensive plasma and peritoneal dialyses fluid sampling. Following a washout phase, the patients will then receive dalbavancin instilled into their peritoneal space followed by the same intensive plasma and peritoneal dialyses fluid sampling.
Interventions
- DRUG Dalbavancin via Intravenous Administration
- DRUG Dalbavancin via Intraperitoneal Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2018-06-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02940730
The ClinicalTrials.gov registry entry for NCT02940730 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dalbavancin via Intravenous Administration is the first listed.
NCT02940730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02940730 about?
NCT02940730 is a clinical study titled "Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients". This study will evaluate the pharmacokinetic properties of dalbavancin when administered as an intravenous infusion and instilled into the peritoneal space in patients who are undergoing peritoneal dialysis. The patients will receive intravenous dalbavancin followed by intensive plasma and peritonea...
What is the current status of trial NCT02940730?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2017-05-01. Estimated completion is 2018-06-18.
What interventions are being tested in trial NCT02940730?
The interventions under investigation include: Dalbavancin via Intravenous Administration (DRUG), Dalbavancin via Intraperitoneal Administration (DRUG).
Who is sponsoring clinical trial NCT02940730?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.